Arcutis Biotherapeutics, Inc. ARQT
27.00 USD -7.05 (-20.70%)
At closeNov 5, 2026, 4:29 PM EST
26.57 -0.43 -1.59%
After hours · Nov 5, 4:29 PM ET
26.77 Day range 29.49
19.30 52-week range 34.80
- YTD
- -7.02%
- 1 year
- +10.75%
- Market cap
- 3.39B
- Revenue (ttm)
- 463.98M
- Profit margin
- 6.15%
- EPS (ttm)
- 0.22
- Shares out
- 125.69M
- P/E ratio
- 122.73
- Forward P/E
- 20.17
- YTD return
- -7.02%
- 1-year return
- +10.75%
- Volume
- 7.60M
- Avg volume
- 2.51M
- Open
- 29.00
- Previous close
- 34.05
- Day's range
- 26.77 – 29.49
- 52-week range
- 19.30 – 34.80
- Beta
- 1.63
- Price target
- 39.13 (+44.9%)
- Earnings date
- Feb 24, 2027
5D -5.22 (-16.20%)
Key statistics
- Enterprise value
- 4.16B
- PEG ratio
- 0.00
- Price / sales
- 7.31
- Price / book
- 17.58
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 59.30%
- Free cash flow
- 21.69M
- Total cash
- 238.55M
- Total debt
- 114.14M
- Return on equity
- 15.86%
- Short % of float
- 17.38%
- 50-day average
- 27.11
- 200-day average
- 25.34
Analyst view
Price target (mean) 39.13 +44.9% upside
Now 27.00
- Target (low)
- 34.00
- Target (mean)
- 39.13
- Target (high)
- 48.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy2
- Buy5
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.23167.
Financials — quick view
ARQT Revenue — quarterly 129.86M
ARQT Net income — quarterly 15.01M
ARQT EPS — quarterly 0.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 0.22 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.18 | 0.06 | -0.12 | -66.67% |
| Aug 5, 2026 | Jun 30, 2026 | 0.05508 | 0.11 | +0.05 | +99.71% |
| May 6, 2026 | Mar 31, 2026 | -0.02 | -0.09 | -0.07 | -350.00% |
| Feb 25, 2026 | Dec 31, 2025 | 0.03 | 0.13 | +0.10 | +333.33% |
| Oct 28, 2025 | Sep 30, 2025 | -0.10 | 0.06 | +0.16 | +160.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | TD Cowen | main | Buy | Buy |
| Oct 19, 2026 | Guggenheim | main | Buy | Buy |
| Oct 15, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Aug 6, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 6, 2026 | Guggenheim | main | Buy | Buy |
| Aug 6, 2026 | Needham | main | Buy | Buy |
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arcutis.com
News
TD Cowen Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40 
Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session - Arcutis Biotherapeutics Initiates Enrollment In Its INTEGUMENT-3 Trial To Evaluate ZORYVE To Treat Atopic Dermatitis
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket 
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call Transcript 
Arcutis Biotherapeutics Q3 Earnings Call Highlights 
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates 
Arcutis Biotherapeutics Announces $200M At-The-Market Common Stock Offering
Your note
Sign in to keep a note on ARQT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNETT PATRICK | Officer | Sale | Nov 1, 2026 | 116,649 |
| CHAUDHURI BHASKAR | Director | Stock Award(Grant) | Jun 11, 2025 | 917,807 |
| EDWARDS LARRY TODD | Officer | Sale | Mar 1, 2026 | 175,178 |
| HERON PATRICK J | Director | Stock Award(Grant) | Jun 4, 2026 | 8,868,640 |
| MATSUDA MASARU | Officer | Conversion of Exercise of derivative security | Nov 3, 2026 | 111,289 |
| PEETZ CHRISTOPHER | Director | Stock Award(Grant) | Jul 14, 2026 | 191,815 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Montanova Capital LLC | 9.89% | 12,437,000 | 335.80M | Jun 29, 2026 |
| Blackrock Inc. | 8.39% | 10,545,466 | 284.73M | Jun 29, 2026 |
| Frazier Life Sciences Management, L.P. | 7.86% | 9,874,511 | 266.61M | Jun 29, 2026 |
| Rubric Capital Management LP | 6.58% | 8,271,577 | 223.33M | Jun 29, 2026 |
| Polar Capital Holdings PLC | 5.26% | 6,606,945 | 178.39M | Jun 29, 2026 |
| State Street Corporation | 4.63% | 5,822,840 | 157.22M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.42% | 6,810,517 | 183.88M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.84% | 3,564,957 | 96.25M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.40% | 3,020,203 | 81.55M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.35% | 2,959,244 | 79.90M | Sep 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 1.17% | 1,466,411 | 39.59M | Sep 29, 2026 |
| Prudential Jennison Small Co Fd., Inc.-PGIM JENNISON SMALL COMPANY Fd. | 1.10% | 1,386,237 | 37.43M | Jun 29, 2026 |